Subjects may either receive or not receive antiretroviral therapy at the time of enrollment
Plasma HIV-1 RNA higher than 5000 copies/ml
OR
Patient CD4+ cell count less than 500 cells/mm3
Patients who can comply with protocol requirements
You may not be if
Patients incapable of oral intake
Patients who are allergic to rice
Pregnant or breast-feeding women
Active drug abuse which, in the opinion of the investigator, is expected to interfere with the subject's ability to adhere to the study procedures
Active, clinically-significant disease or life-threatening disease that would compromise the subject's safety or outcome of the study
Any medical or psychiatric condition which, in the opinion of the investigator, could compromise the subject's safety or adherence to the trial protocol
Patients who have started their anti-HIV treatment within less than 3 months from inclusion in the study. However, patients who have changed anti-HIV medication but have initiated therapy more than 3 months before inclusion will be eligible for the study.
Patients known to suffer from diabetes mellitus
Participation in any other clinical trial
Clareo Health | RiSolubles™, the Soluble Fraction of Rice Bran for HIV-Infected Patients
